Colorectal Cancer Alliance, shared on X:
“Targeted therapies are transforming cancer care, yet many patients never receive the biomarker testing that could reveal more effective, potentially less toxic treatment options.
That urgency is driving KLEOS, the Alliance’s adaptive clinical trial platform.
By evaluating multiple promising colorectal cancer therapies more efficiently and expanding access to cutting-edge options, KLEOS aims to move breakthroughs from the lab to patients faster—because innovation only matters when patients can benefit from it.
Read this article from The New York Times to learn why too many patients are missing out on groundbreaking treatments and what needs to change.”
You may also read:
Early-Onset Colorectal Cancer: Recognition, Workup and Treatment Selection